Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 3
Launched by L. CINNAMON BIDWELL · Oct 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how cannabis affects memory and attention in healthy adults who regularly use cannabis. Specifically, researchers want to see how two compounds found in cannabis, THC and CBD, influence memory recognition tasks. Participants will try two different strains of cannabis on separate days and complete a memory test while their brain activity is monitored with a device called an electroencephalogram (EEG). Researchers will also collect blood samples to measure how much THC and CBD they have in their system, along with gathering information about the participants' health and lifestyle.
To be eligible for this study, participants should be between 21 and 40 years old, right-handed, and regular cannabis users (at least four times in the past month). They should not be using other recreational drugs or certain medications, and females must not be pregnant. Participants can expect to take part in memory tasks on two different days, providing information about their health and lifestyle, and having their brain activity measured. This research aims to better understand how cannabis use impacts cognitive functions like memory in daily life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Must be between the ages of 21 and 40 and provide informed consent;
- • 2. Must be right-handed (Laterality Quotient \> 60 on Edinburgh Handedness Inventory - Short Form);
- • 3. Must use cannabis at least 4 days during the month;
- • 4. Must be a cannabis user for at least a year;
- • 5. Must self-report not using other illicit recreational drugs (e.g., cocaine, benzodiazepines (non-prescription), opiates (non-prescription), MDMA, sedatives, or methamphetamine) in the past 30 days, during the Pre-Screening;
- • 6. Must not test positive on a urine toxicology test for drugs of abuse at the Baseline appointment;
- • 7. Must not be using psychotropic medications, however anti-depressant, non-benzodiazepine anti-anxiety, and ADHD medications are ok. ADHD medication users must be willing to abstain from ADHD medication use on appointment days;
- • 8. Must not be a regular nicotine user (≤4 days per week; cigarette, E-cigs, or smokeless);
- • 9. Must not have used caffeine or nicotine (cigarette, E-cigs, or smokeless) for 4 hours before each appointment;
- • 10. Must have a breath alcohol level of 0 at Baseline appointment (to sign consent form);
- • 11. Must not be actively seeking or in treatment for any substance use disorder;
- • 12. Female subjects must not be or trying to become pregnant (as indicated by a pregnancy test administered at Baseline appointment);
- • 13. Must not be in treatment for psychotic disorder or bipolar disorder; or have a history with these disorders;
- • 14. Must not have any physical characteristics (e.g., thick hair, head size exceeding the limit of the net, dyed hair) or experience any technical difficulties during testing that result in a poor-quality EEG recording.
About L. Cinnamon Bidwell
L. Cinnamon Bidwell is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative therapeutic solutions. With a strong focus on designing and implementing rigorous clinical studies, Bidwell leverages a multidisciplinary approach that integrates scientific expertise and patient-centric methodologies. The organization is dedicated to collaboration with healthcare professionals and regulatory bodies, ensuring compliance with ethical standards and regulatory requirements. By prioritizing transparency and quality, L. Cinnamon Bidwell aims to contribute significantly to the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boulder, Colorado, United States
Patients applied
Trial Officials
Timothy Curran, PhD
Principal Investigator
University of Colorado, Boulder
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported